

VRAAG 1: ECHOGRAFISCHE KENMERKEN PALPABELE NODUS

Systematic reviews

Study ID	Method	Patient characteristics	Intervention(s)	Results primary outcome	Critical appraisal of review quality
Gharib H 2010	<ul style="list-style-type: none"> • SR (guideline) • Funding/Col: list provided in article • Search date: not reported • Databases: Medline, Cochrane Library, National Guideline Clearinghouse, AHRQ, CMA, etc. • Study designs: SR, guidelines, primary studies • N included studies: unclear 	<ul style="list-style-type: none"> • Eligibility criteria: patients with palpable nodus 	US criteria for FNAB	Diagnosis of malignancy: <ul style="list-style-type: none"> • Marked hypoechogenicity: Sp 41.4-92.2% • Microcalcifications: Sp 44.2-95.0% • Irregular or microlobulated margin: Sp 48.3-91.8% • Chaotic arrangement or intranodular vascular images: Sp 80% • All features have low Se 	Level of evidence: B <ul style="list-style-type: none"> • Unclear how quality appraisal was done, but use of levels of evidence and grades of recommendation • No results provided for individual studies

Primaire studies

Study ID	Method	Patient characteristics	Intervention(s)	Results primary outcome	Critical appraisal of study quality
Popli MB 2012	<ul style="list-style-type: none"> • Diagnostic accuracy study • Funding/Col: no funding, no Col declared • Setting: single centre, India • Sample size: N=203 • Duration: inclusion 9/2009-8/2010 	<ul style="list-style-type: none"> • Eligibility criteria: patients with clinically palpable thyroid nodules referred for investigation; no multinodular goiter (N=73); size at least 1 cm; no purely cystic nodule; no inadequate FNAC • <i>A priori</i> patient characteristics: females 92%, age 15-62y • Prevalence: 18.3% malignant nodules 	<p><u>Index test:</u> Neck US</p> <p><u>Reference test:</u> Cytopathology (US-FNAC)</p>	<p>Diagnosis of malignancy:</p> <p>Poorly defined margins:</p> <ul style="list-style-type: none"> • Se: 84% • Sp: 89% • PPV: 63% • NPV: 96% <p>Calcification:</p> <ul style="list-style-type: none"> • Se: 86% • Sp: 76% • PPV: 45% • NPV: 96% <p>Microcalcification:</p> <ul style="list-style-type: none"> • Se: 66% • Sp: 98% • PPV: 88% • NPV: 93% <p>Macrocalcification:</p> <ul style="list-style-type: none"> • Se: 20% • Sp: 78% • PPV: 17% • NPV: 81% <p>Solid or predominantly solid composition:</p> <ul style="list-style-type: none"> • Se: 89% • Sp: 54% • PPV: 30% • NPV: 95% <p>Absent or thick irregular halo:</p> <ul style="list-style-type: none"> • Se: 70% • Sp: 66% • PPV: 32% • NPV: 91% <p>Markedly hypoechoic:</p> <ul style="list-style-type: none"> • Se: 66% • Sp: 87% • PPV: 54% • NPV: 92% <p>Shape taller than wide:</p> <ul style="list-style-type: none"> • Se: 77% • Sp: 80% 	<p>Level of evidence: B</p> <ul style="list-style-type: none"> • Unclear if consecutive patients • Blinded image review, unclear if pathology review was blinded • Only per-lesion analysis

Study ID	Method	Patient characteristics	Intervention(s)	Results primary outcome	Critical appraisal of study quality
				<ul style="list-style-type: none"> • PPV: 47% • NPV: 94% 	
Polyzos SA 2009	<ul style="list-style-type: none"> • Diagnostic accuracy study, retrospective • Funding/Col: funding not reported, no Col declared • Setting: single university centre, Greece • Sample size: N=796 • Duration: inclusion 1987-2004 	<ul style="list-style-type: none"> • Eligibility criteria: patients with a palpable solitary thyroid nodule or at least one dominant nodule within a multinodular goiter detected by clinical examination, US or both; at least one US before any medical intervention; at least one thyroid FNAB • <i>A priori</i> patient characteristics: females 87%, mean age 48.2y • Prevalence: 8.7% patients with malignant nodules 	<p><u>Index test:</u> Neck US</p> <p><u>Reference test:</u> FNAB</p>	<p>Diagnosis of malignancy:</p> <p>Solitary nodule:</p> <ul style="list-style-type: none"> • Se: 57% (28/49) • Sp: 68% (347/509) • PPV: 15% (28/190) • NPV: 94% (347/368) <p>Solid composition:</p> <ul style="list-style-type: none"> • Se: 58% (23/40) • Sp: 48% (208/435) • PPV: 9% (23/250) • NPV: 92% (17/225) <p>US diameter at least 4.5 cm:</p> <ul style="list-style-type: none"> • Se: 15% (5/33) • Sp: 95% (390/412) • PPV: 19% (5/27) • NPV: 93% (390/418) 	<p>Level of evidence: B</p> <ul style="list-style-type: none"> • 941 consecutive patients, 796 of which underwent US • Exclusion of patients with indeterminate and non-diagnostic cytology, or benign cytology if followed for less than 1 year; unclear why different number of patients per US-criterion • Blinding not reported
Lin JH 2009	<ul style="list-style-type: none"> • Diagnostic accuracy study, retrospective • Funding/Col: not reported • Setting: single university centre, Taiwan • Sample size: N=317 • Duration: inclusion 1/1993-12/2006 	<ul style="list-style-type: none"> • Eligibility criteria: patients with palpable thyroid nodules that underwent thyroid total lobectomy or TT; no locally advanced thyroid nodules or distal metastases, known thyroid disease, radiation therapy to head and neck area • <i>A priori</i> patient characteristics: females 74%, mean age 43.5y • Prevalence: 21.4% malignant nodules 	<p><u>Index test:</u> Neck US (real-time ultrasonographic scanner)</p> <p><u>Reference test:</u> Histopathology</p>	<p>Diagnosis of malignancy:</p> <ul style="list-style-type: none"> • Se: 52% • Sp: 94% • PPV: 64% • NPV: 90% 	<p>Level of evidence: B</p> <ul style="list-style-type: none"> • Important selection bias by only selecting patients that underwent surgery • 317 out of 378 included patients underwent US • US criteria for malignancy = at least one of the following: solid echo structure, hypoechogenicity, fine calcification, and ill-defined margin
Alexander EK 2004	<ul style="list-style-type: none"> • Diagnostic accuracy study, retrospective • Funding/Col: not reported, but 1 author collaborates with Pfizer • Setting: single centre, US • Sample size: N=747 • Duration: inclusion 1995-2000 	<ul style="list-style-type: none"> • Eligibility criteria: patients with at least 1 solid (less than 25% cystic) thyroid nodule evaluated with US-guided FNA • <i>A priori</i> patient characteristics: females: benign 89% vs. malignant 86%; mean age: 50 vs. 45y; maximal size: 25 +/- 12 mm vs. 24 +/- 11 mm • Prevalence: 13.9% malignant nodules 	<p><u>Index test:</u> Neck US</p> <p><u>Reference test:</u> FNA and/or surgical pathology</p>	<p>Diagnosis of malignancy:</p> <p>Solitary nodule:</p> <ul style="list-style-type: none"> • Se: 46% (48/104) • Sp: 70% (447/643) • PPV: 20% (48/244) • NPV: 89% (447/503) 	<p>Level of evidence: B</p> <ul style="list-style-type: none"> • Selection of patients not clearly reported: selection criteria? Why did they receive US? • Consecutive patients, inclusion based on receiving of reference test • Blinding not reported • No 2x2 tables possible for ratio of longest to shortest axis
Asteria C 2008	<ul style="list-style-type: none"> • Diagnostic accuracy study, prospective • Funding/Col: not reported • Setting: single centre, Italy 	<ul style="list-style-type: none"> • Eligibility criteria: patients with thyroid nodules who were referred to the Thyroid Unit of the Department of Endocrinology and Cardiovascular Prevention at the Policlinico MultiMedica; presence 	<p><u>Index test:</u> Neck US: (1) US B-mode and US color-power-Doppler; (2) free-hand real-time US-elastography</p>	<p>Diagnosis of malignancy:</p> <p>Hypoechogenicity:</p> <ul style="list-style-type: none"> • Se: 65% • Sp: 81% • PPV: 46% 	<p>Level of evidence: B</p> <ul style="list-style-type: none"> • Selection of patients not clearly reported: selection criteria? Why did they receive US? • Consecutive patients

Study ID	Method	Patient characteristics	Intervention(s)	Results primary outcome	Critical appraisal of study quality
	<ul style="list-style-type: none"> Sample size: N=67 Duration: inclusion 1/2006-12/2006 	<p>of single or multiple thyroid nodules >10mm; no anatomical abnormalities of the neck (i.e., bull neck) and cystic lesions of completely liquid nature</p> <ul style="list-style-type: none"> <i>A priori</i> patient characteristics: females 81%, age range 23-83y, mean size 21.3 mm (range 10-50 mm) Prevalence: 19.8% malignant nodules 	<p><u>Reference test:</u> FNAB or surgical pathology</p>	<ul style="list-style-type: none"> NPV: 90% <p>Microcalcification:</p> <ul style="list-style-type: none"> Se: 59% Sp: 84% PPV: 48% NPV: 89% <p>Irregular margins:</p> <ul style="list-style-type: none"> Se: 76% Sp: 78% PPV: 46% NPV: 93% <p>Absence of halo sign:</p> <ul style="list-style-type: none"> Se: 100% Sp: 14% PPV: 22% NPV: 100% <p>Hypoechoogenicity + irregular margins:</p> <ul style="list-style-type: none"> Se: 65% Sp: 93% PPV: 69% NPV: 91% <p>Hypoechoogenicity + microcalcifications:</p> <ul style="list-style-type: none"> Se: 41% Sp: 93% PPV: 58% NPV: 86% <p>Irregular margins + microcalcifications:</p> <ul style="list-style-type: none"> Se: 53% Sp: 96% PPV: 75% NPV: 89% <p>Hypoechoogenicity + irregular margins + microcalcifications:</p> <ul style="list-style-type: none"> Se: 41% Sp: 99% PPV: 88% NPV: 87% <p>Elasticity score 3-4:</p> <ul style="list-style-type: none"> Se: 94% Sp: 81% PPV: 55% 	<ul style="list-style-type: none"> Blinded US-evaluation, unclear if blinded pathology review Differential verification Per-lesion analysis

Study ID	Method	Patient characteristics	Intervention(s)	Results primary outcome	Critical appraisal of study quality
Friedrich-Rust 2010	<ul style="list-style-type: none"> Diagnostic accuracy study Funding/Col: funding not reported; no Col to declare Setting: single University centre, Germany Sample size: N=50 Duration: inclusion 6/2007-1/2009 	<ul style="list-style-type: none"> Eligibility criteria: patients presenting for workup of thyroid nodules ≥ 10 mm, non-functioning or hypo-functioning on radionuclide scanning, and FNAB of this nodule performed within the last 3 months or FNAB and/or surgery planned at the time of US examination and finally performed within the study period; no cystic lesions of completely liquid nature, pregnancy, heart failure NYHA III-IV, severe pulmonary hypertension <i>A priori</i> patient characteristics: females 74%, age range 26-79y Prevalence: 13.2% malignant nodules 	<p><u>Index test:</u> Neck US: (1) conventional US; (2) real-time US-elastography; (3) contrast-enhanced US</p> <p><u>Reference test:</u> FNAB or surgical pathology</p>	<ul style="list-style-type: none"> NPV: 98% <p>Diagnosis of malignancy:</p> <p>Hypoechoogenicity:</p> <ul style="list-style-type: none"> Se: 43% Sp: 59% PPV: 14% NPV: 87% <p>Microcalcification:</p> <ul style="list-style-type: none"> Se: 43% Sp: 76% PPV: 21% NPV: 90% <p>Absence of halo sign:</p> <ul style="list-style-type: none"> Se: 57% Sp: 39% PPV: 13% NPV: 86% <p>Irregular margins:</p> <ul style="list-style-type: none"> Se: 57% Sp: 85% PPV: 36% NPV: 93% <p>Oval shape:</p> <ul style="list-style-type: none"> Se: 29% Sp: 65% PPV: 11% NPV: 86% <p>Pattern 4 vascularity:</p> <ul style="list-style-type: none"> Se: 29% Sp: 91% PPV: 33% NPV: 89% <p>Pattern 3-4 vascularity:</p> <ul style="list-style-type: none"> Se: 71% Sp: 46% PPV: 17% NPV: 91% <p>Elasticity score 3-4:</p> <ul style="list-style-type: none"> Se: 86% Sp: 87% PPV: 50% 	<p>Level of evidence: B</p> <ul style="list-style-type: none"> Unclear if consecutive patients Blinded US-evaluation, unclear if blinded pathology review Differential verification Per-lesion analysis

Study ID	Method	Patient characteristics	Intervention(s)	Results primary outcome	Critical appraisal of study quality
Kwak JY 2011	<ul style="list-style-type: none"> Diagnostic accuracy study, retrospective Funding/Col: supported by a faculty research grant from Yonsei University College of Medicine; no Col to declare Setting: single University centre, Korea Sample size: N=1638 Duration: inclusion 5/2008-12/2008 	<ul style="list-style-type: none"> Eligibility criteria: patients that underwent US-FNAB for nodules of at least 1 cm <i>A priori</i> patient characteristics: mean age 50.6y, mean size 19.9 mm (range 10-80 mm) Prevalence: 16.6% malignant nodules 	<p><u>Index test:</u> Neck US</p> <p><u>Reference test:</u> FNAB or surgical pathology</p>	<p>NPV: 98%</p> <p>Diagnosis of malignancy:</p> <p>Solid composition:</p> <ul style="list-style-type: none"> Se: 93% Sp: 42% PPV: 24% NPV: 97% <p>(Marked) hypoechogenicity:</p> <ul style="list-style-type: none"> Se: 84% Sp: 62% PPV: 31% NPV: 95% <p>Irregular margins:</p> <ul style="list-style-type: none"> Se: 33% Sp: 99% PPV: 86% NPV: 88% <p>Microcalcification:</p> <ul style="list-style-type: none"> Se: 40% Sp: 96% PPV: 69% NPV: 89% <p>Taller than wide shape:</p> <ul style="list-style-type: none"> Se: 51% Sp: 96% PPV: 71% NPV: 91% 	<p>Level of evidence: B</p> <ul style="list-style-type: none"> Consecutive patients Blinding not clearly reported Differential verification Per-lesion analysis
Tamsel S 2007	<ul style="list-style-type: none"> Diagnostic accuracy study, prospective Funding/Col: not reported Setting: single University centre, Turkey Sample size: N=134 Duration: inclusion 6/2005-12/2005 	<ul style="list-style-type: none"> Eligibility criteria: not clearly reported <i>A priori</i> patient characteristics: females 80%, mean age 48y, mean size 19.1 mm (range 10-60 mm) Prevalence: 6% malignant nodules 	<p><u>Index test:</u> Neck power Doppler US</p> <p><u>Reference test:</u> FNAB or surgical pathology</p>	<p>Diagnosis of malignancy:</p> <p>Intranodular vascularity:</p> <ul style="list-style-type: none"> Se: 100% Sp: 11% PPV: 6% NPV: 100% 	<p>Level of evidence: B</p> <ul style="list-style-type: none"> Unclear if consecutive patients, inclusion criteria not reported Blinded evaluation of imaging and pathology Per-lesion analysis
Yoon JH 2011	<ul style="list-style-type: none"> Diagnostic accuracy study, retrospective Funding/Col: funding not reported; no Col to declare Setting: single University centre, Korea 	<ul style="list-style-type: none"> Eligibility criteria: patients that underwent US-FNAB for initial diagnosis of thyroid nodules 3 cm or larger in the longest diameter on US <i>A priori</i> patient characteristics: females 82%, mean age 48y, 	<p><u>Index test:</u> Neck US</p> <p><u>Reference test:</u> FNAB + findings on follow-up US, or surgical pathology</p>	<p>Diagnosis of malignancy:</p> <p>Solid composition:</p> <ul style="list-style-type: none"> Se: 12% Sp: 96% PPV: 26% NPV: 90% 	<p>Level of evidence: B</p> <ul style="list-style-type: none"> Unclear if consecutive patients Blinded US-evaluation, unclear if blinded pathology review Incorporation bias Differential verification

Study ID	Method	Patient characteristics	Intervention(s)	Results primary outcome	Critical appraisal of study quality
	<ul style="list-style-type: none"> • Sample size: N=661 • Duration: inclusion 2/2002-12/2006 	<p>mean size 39 mm (range 30-150 mm)</p> <ul style="list-style-type: none"> • Prevalence: 11.2% malignant nodules 		<p>(Marked) hypoechogenicity:</p> <ul style="list-style-type: none"> • Se: 76% • Sp: 70% • PPV: 24% • NPV: 96% <p>Ill-defined margin:</p> <ul style="list-style-type: none"> • Se: 15% • Sp: 100% • PPV: 92% • NPV: 90% <p>Microcalcification:</p> <ul style="list-style-type: none"> • Se: 19% • Sp: 99% • PPV: 70% • NPV: 91% <p>Non-parallel shape:</p> <ul style="list-style-type: none"> • Se: 4% • Sp: 100% • PPV: 60% • NPV: 89% 	<ul style="list-style-type: none"> • Per-lesion analysis

Abbreviations: AHRQ: Agency for Healthcare Research and Quality; CMA: ...; Col: conflict of interest; FNAB: fine-needle aspiration biopsy; FNAC: fine-needle aspiration cytology; NPV: negative predictive value; PPV: positive predictive value; Se: sensitivity; Sp: specificity; SR: systematic review; TT: total thyroidectomy; US: ultrasonography.

References

- Alexander EK, Marqusee E, Orcutt J, Benson CB, Frates MC, Doubilet PM, et al. Thyroid nodule shape and prediction of malignancy. *Thyroid*. 2004;14(11):953-8.
- Asteria C, Giovanardi A, Pizzocaro A, Cozzaglio L, Morabito A, Somalvico F, et al. US-elastography in the differential diagnosis of benign and malignant thyroid nodules. *Thyroid*. 2008;18(5):523-31.
- Friedrich-Rust M, Sperber A, Holzer K, Diener J, Grunwald F, Badenhoop K, et al. Real-time elastography and contrast-enhanced ultrasound for the assessment of thyroid nodules. *Exp Clin Endocrinol Diabetes*. 2010;118(9):602-9.
- Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. *J. Endocrinol. Invest.* 2010;33(5 SUPPL.):1-50.
- Kwak JY, Han KH, Yoon JH, Moon HJ, Son EJ, Park SH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. *Radiology*. 2011;260(3):892-9.
- Lin J-H, Chiang F-Y, Lee K-W, Ho K-Y, Kuo W-R. The role of neck ultrasonography in thyroid cancer. *Am J Otolaryngol*. 2009;30(5):324-6.
- Polyzos SA, Kita M, Efstathiadou Z, Goulis DG, Benos A, Flaris N, et al. The use of demographic, ultrasonographic and scintigraphic data in the diagnostic approach of thyroid nodules. *Exp Clin Endocrinol Diabetes*. 2009;117(4):159-64.
- Popli MB, Rastogi A, Bhalla PJS, Solanki Y. Utility of gray-scale ultrasound to differentiate benign from malignant thyroid nodules. *Indian J. Radiol. Imaging*. 2012;22(1):63-8.
- Tamsel S, Demirpolat G, Erdogan M, Nart D, Karadeniz M, Uluer H, et al. Power Doppler US patterns of vascularity and spectral Doppler US parameters in predicting malignancy in thyroid nodules. *Clin Radiol*. 2007;62(3):245-51.
- Yoon JH, Kwak JY, Moon HJ, Kim MJ, Kim E-K. The diagnostic accuracy of ultrasound-guided fine-needle aspiration biopsy and the sonographic differences between benign and malignant thyroid nodules 3[THIN SPACE]cm or larger. *Thyroid*. 2011;21(9):993-1000.